In other Sarepta Therapeutics news, SVP Shamim Ruff sold 10,000 shares of the company's stock in a transaction that occurred on Monday, November 6th. The hedge fund run by Jason Karp held 895,000 shares of the health care company at the end of 2017Q3, valued at $40.60M, up from 331,400 at the end of the previous reported quarter. Investors who are keeping close eye on the stock of Sarepta Therapeutics, Inc. The stock increased 0.23% or $0.28 during the last trading session, reaching $123.43. The stock was acquired at an average price of $52.44 per share, for a total transaction of $1,999,956.72. Avery Dennison Corporation (NYSE:AVY) has risen 10.91% since January 14, 2017 and is uptrending. It has outperformed by 80.12% the S&P500.
Shelter Mutual Insurance Co decreased its stake in Jm Smucker Co (SJM) by 8.53% based on its latest 2017Q3 regulatory filing with the SEC. The shares were sold at an average price of $55.00, for a total value of $550,000.00. The institutional investor held 354,252 shares of the consumer services company at the end of 2017Q3, valued at $18.45 million, up from 330,879 at the end of the previous reported quarter. Prudential Plc who had been investing in 3M Company for a number of months, seems to be less bullish one the $145.61B market cap company. The overall volume in the last trading session was 1.63 million shares. About 1.25M shares traded. Motorola Solutions, Inc. (NYSE:MSI) has risen 17.62% since January 12, 2017 and is uptrending. It has underperformed by 3.50% the S&P500.
Advantus Capital Management Inc, which manages about $27.77B and $3.85B US Long portfolio, decreased its stake in Uniti Group Inc by 56,283 shares to 130,351 shares, valued at $1.91 million in 2017Q3, according to the filing. (NASDAQ:SRPT) or 716,772 shares.
Investors sentiment decreased to 1.26 in Q3 2017. The company reported ($0.95) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.32) by $0.37. It is positive, as 16 investors sold HIW shares while 67 reduced holdings. 51 funds opened positions while 159 raised stakes. (NYSE:HIW). Quantitative Systematic Strategies Limited Liability has 4,877 shares. Goldman Sachs Group holds 664,963 shares. Fiera Corporation reported 164,842 shares stake. Louisiana State Employees Retirement reported 0.07% in Highwoods Properties, Inc. Highlander Cap Mngmt Llc owns 500 shares. Washington Bank & Trust, a Washington-based fund reported 1,114 shares. Manchester Capital Management Llc reported 2,161 shares. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. C (NYSE:FCB) stake by 8,960 shares and now owns 46,064 shares. Dodge Cox holds 0% or 18,915 shares in its portfolio. Moreover, Middleton Inc Ma has 0.14% invested in 3M Company (NYSE:MMM). (NYSE:HIW). Putnam Fl Investment Management Communication accumulated 242,563 shares.
Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. Avery Dennison had 25 analyst reports since October 15, 2015 according to SRatingsIntel. The company presently has a consensus rating of Buy and a consensus target price of $63.88. The stock has "Buy" rating by Needham on Tuesday, September 20. As per Wednesday, January 25, the company rating was maintained by Stifel Nicolaus. Savant Capital Llc bought 527 shares as the company's stock rose 13.58% with the market. The stock of Amazon.com, Inc. (NASDAQ:AMZN) earned "Outperform" rating by Credit Suisse on Friday, October 23. The stock has "Hold" rating by Deutsche Bank on Thursday, August 6. Nomura reissued a buy rating and set a $84.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, September 5th. The firm has "Buy" rating by J.P. Morgan given on Wednesday, September 6. The stock has "Neutral" rating by Wedbush on Thursday, April 21.
Investors sentiment increased to 2.88 in 2017 Q3. Advantage reported 31,051 shares. It is positive, as 24 investors sold SRPT shares while 27 reduced holdings. Jennison Associates LLC raised its stake in Sarepta Therapeutics by 103.9% in the third quarter. (NASDAQ:SRPT). Gp One Trading Lp has 0.08% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Gotham Asset Limited Liability Company reported 9,268 shares. Healthcor Mgmt Limited Partnership holds 1.83% of its portfolio in Sarepta Therapeutics, Inc. LLC lifted its position in shares of Sarepta Therapeutics by 3,599.4% in the 3rd quarter. (NASDAQ:SRPT) for 26,491 shares. 952 were accumulated by Crow Point Partners Ltd Liability Company. Lingnau Lutz also sold $109,850 worth of Nektar Therapeutics (NASDAQ:NKTR) shares. Marvin Palmer Assoc reported 40 shares. Sarepta Therapeutics has a 12 month low of $26.26 and a 12 month high of $61.89. (NASDAQ:SRPT) for 893,484 shares. (NASDAQ:SRPT). Tiaa Cref Investment Mgmt Limited Liability owns 0.01% invested in Sarepta Therapeutics, Inc. Great West Life Assurance Can reported 219,136 shares. 23,212 are held by Biondo Invest Advisors Limited Liability Company. Ameriprise Fin has 109,080 shares. Therefore 32% are positive. Credit Suisse Group upped their target price on shares of Sarepta Therapeutics from $5.65 to $81.00 and gave the company an "outperform" rating in a research report on Thursday, September 7th. (NYSE:MSI) earned "Neutral" rating by Macquarie Research on Wednesday, February 24. The firm has "Buy" rating by Bank of America given on Friday, October 23. The rating was downgraded by RBC Capital Markets to "Sector Perform" on Tuesday, January 19. They set a "buy" rating and a $75.00 price objective for the company. Barclays Capital initiated Sarepta Therapeutics, Inc. On Monday, September 19 the stock rating was maintained by Robert W. Baird with "Outperform". Vanguard Group Inc. boosted its stake in Sarepta Therapeutics by 4.0% during the 2nd quarter.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Thursday, October 27th. (NYSE:MSI) earned "Hold" rating by Jefferies on Monday, December 7. The rating was maintained by Oppenheimer on Wednesday, June 7 with "Buy". The firm has "Buy" rating by Roth Capital given on Thursday, August 20.
Oppenheimer also issued estimates for Sarepta Therapeutics' Q4 2017 earnings at ($0.26) EPS, FY2018 earnings at ($1.27) EPS, FY2019 earnings at ($0.64) EPS and FY2020 earnings at $2.84 EPS.
Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.